These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26933124)

  • 1. Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing.
    Schrock AB; Frampton GM; Herndon D; Greenbowe JR; Wang K; Lipson D; Yelensky R; Chalmers ZR; Chmielecki J; Elvin JA; Wollner M; Dvir A; -Gutman LS; Bordoni R; Peled N; Braiteh F; Raez L; Erlich R; Ou SH; Mohamed M; Ross JS; Stephens PJ; Ali SM; Miller VA
    Clin Cancer Res; 2016 Jul; 22(13):3281-5. PubMed ID: 26933124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR.
    Chung KP; Wu SG; Wu JY; Yang JC; Yu CJ; Wei PF; Shih JY; Yang PC
    Clin Cancer Res; 2012 Jun; 18(12):3470-7. PubMed ID: 22510346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis.
    Liu HL; Han G; Peng M; Weng YM; Yuan JP; Yang GF; Yu JM; Song QB
    J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):864-872. PubMed ID: 29270745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.
    Suh JH; Schrock AB; Johnson A; Lipson D; Gay LM; Ramkissoon S; Vergilio JA; Elvin JA; Shakir A; Ruehlman P; Reckamp KL; Ou SI; Ross JS; Stephens PJ; Miller VA; Ali SM
    Oncologist; 2018 Jul; 23(7):776-781. PubMed ID: 29540602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
    Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
    Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
    Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Nishinarita N; Igawa S; Kasajima M; Kusuhara S; Harada S; Okuma Y; Sugita K; Ozawa T; Fukui T; Mitsufuji H; Yokoba M; Katagiri M; Kubota M; Sasaki J; Naoki K
    Oncology; 2018; 95(2):109-115. PubMed ID: 29698957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
    Yeo CD; Park KH; Park CK; Lee SH; Kim SJ; Yoon HK; Lee YS; Lee EJ; Lee KY; Kim TJ
    Lung Cancer; 2015 Mar; 87(3):311-7. PubMed ID: 25617986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
    Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
    Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
    J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
    Sequist LV; Martins RG; Spigel D; Grunberg SM; Spira A; Jänne PA; Joshi VA; McCollum D; Evans TL; Muzikansky A; Kuhlmann GL; Han M; Goldberg JS; Settleman J; Iafrate AJ; Engelman JA; Haber DA; Johnson BE; Lynch TJ
    J Clin Oncol; 2008 May; 26(15):2442-9. PubMed ID: 18458038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea.
    Baek JH; Sun JM; Min YJ; Cho EK; Cho BC; Kim JH; Ahn MJ; Park K
    Lung Cancer; 2015 Feb; 87(2):148-54. PubMed ID: 25498243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China.
    Xu J; Zhang Y; Jin B; Chu T; Dong X; Yang H; Wu D; Lou Y; Zhang X; Wang H; Han B
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1325-30. PubMed ID: 26942444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.
    Peters MJ; Bowden JJ; Carpenter P; Lewis J; Solomon B
    Intern Med J; 2014 Jun; 44(6):575-80. PubMed ID: 24720523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
    Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
    Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y; Maemondo M; Ishii Y; Okudera K; Demura Y; Takamura K; Kobayashi K; Morikawa N; Gemma A; Ishimoto O; Usui K; Harada M; Miura S; Fujita Y; Sato I; Saijo Y;
    Lung Cancer; 2014 Nov; 86(2):195-200. PubMed ID: 25249428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.